Schroder Investment Management Group Raises Stake in Pfizer Inc. (NYSE:PFE)

Schroder Investment Management Group increased its stake in Pfizer Inc. (NYSE:PFE) by 13.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,973,310 shares of the biopharmaceutical company’s stock after buying an additional 1,193,722 shares during the period. Schroder Investment Management Group owned 0.18% of Pfizer worth $264,592,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Nordea Investment Management AB boosted its holdings in shares of Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock valued at $108,002,000 after purchasing an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI lifted its holdings in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock worth $7,820,000 after buying an additional 159,984 shares during the period. NFJ Investment Group LLC grew its position in shares of Pfizer by 12.8% during the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company’s stock worth $11,129,000 after buying an additional 43,719 shares in the last quarter. Copley Financial Group Inc. purchased a new position in shares of Pfizer during the third quarter valued at $577,000. Finally, Zacks Investment Management raised its holdings in shares of Pfizer by 10.9% in the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company’s stock valued at $69,142,000 after acquiring an additional 235,243 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.8 %

Shares of NYSE:PFE opened at $25.20 on Friday. The business has a 50-day moving average price of $26.06 and a 200-day moving average price of $26.92. The stock has a market cap of $142.93 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the business posted $0.10 EPS. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.